MS1819 Lipase

• Yeast derived recombinant lipase enzyme
• Oral non-systemic capsule for treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis or chronic pancreatitis
• Superior in vitro characteristics (i.e. high potency, activity in long chain fats, stability in protease and bile salt environments) to pig lipase
• Supply chain immune to pandemic infection to pig herds
• Eliminates pork viral contamination risk
• Vegetarian/Kosher/Halal capsules suitable for all patients including those allergic to pig proteins
• Available clinical safety and efficacy profile shows promise

FW-420 and FW-1022 Niclosamide

• Novel anti-inflammatory and anti-viral properties
• Not systemically absorbed
• Allows for higher local GI concentrations
• Avoids steroid-related complications
• Reduced particle size (~7 𝜇𝑚) compared to regular non-micronized (~60 𝜇𝑚) niclosamide
• Smaller particles have greater surface to solvent (GI fluids) ratio
• Improved dissolution: broader distribution and higher local GI concentrations
• Preclinical studies confirm higher GI concentrations (~200x) with micronized niclosamide
• Niclosamide has a historically clean safety profile – approved by the FDA in 1982 and used on millions of patients